网友提问:
恒瑞医药(600276)
研报日期:2018-10-22 恒瑞医药(600276) A market leader for almost all flagship drugs We analyzed competitive landscape of Hengrui’s top 10 drugs including Aitan(apatinib), Aibeining, Aisu, and atracurium series. All together, they took in66% of total revenue in 1H18 by Rx data. Hengrui maintained its No. 1 rank inmany of the chemical classes in the past 4.5 years. Also, most of the 10 drugsexperienced single-digit price cuts during the period, except for Aitan, whoseASP was slashed 37% in 1H18 upon NRDL entry. We now model 21% and27% growth for net income in 2018 and 2019, respectively. Expect limit
网友回复
绿地控股606叶:
发表于 2018-10-2216:43:36股友KlIh8c:
翻译一下什么好消息?
李子湖:
德意志很行分析了恒瑞的各种药物收入,龙头,买入
STEVEN47894:
目标价73.9至83.9
pad2014:
你丫注册就是来唱空的,就问一句,减持那么多都给谁了?给你了?给小散了?
hei嘿hei:
德意志银行?他们买了没?
STEVEN47894:
85.5
ceancow:
别理精神病患者
ceancow:
目标价73-85 不过德银本身其实一般
绿地控股606:
港资狂卖7.84亿说明什么?
AlanMYB:
你SB一个不看好此票……干嘛还天天在这瞎BB